RE: C4xd12 Apr 2018 08:58
Deal update
-- On 29 March 2018, post-period end, C4XD announced a licensing deal with Indivior worth up to $294 million for C4XD's oral Orexin-1 receptor antagonist for the treatment of addiction, receiving $10 million upfront. The treatment of addiction represents a substantial area of unmet medical need, forecast to be worth an estimated $13 billion per annum in 2018(1) .
Discovery Engine progress
-- Following the out-licensing of C4XD's IND-ready Orexin-1 programme to Indivior, the Company now has three lead drug discovery programmes showing in vivo activity, opening up a path to candidate selection and opportunity to progress to partnering discussions.
-- C4XD's proprietary drug asset portfolio of ten programmes across a number of therapeutic areas, including inflammation, neurodegeneration, immuno-oncology, addiction and diabetes, has progressed towards revenue generation.
Innovative technologies to advance drug development
-- A new version of the Taxonomy3(R) software was released in late 2017 which has doubled the analysis speed for gene-gene interaction and continued investment in the software will result in C4XD being capable of analysing six disease datasets per annum.
-- C4XD has initiated the creation of a specialised visualiser ("4Sight") to allow the viewing of C4XD's proprietary 4D molecular data to provide a revolutionary way of viewing and comparing molecules in a virtual world utilising the latest VR technology.
-- 4Sight has been chosen as a case study for Immerse UK which is supporting the UK in becoming the global leader in the application of immersive technologies.
Sign In
Follow the stocks
